Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.42 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | CA12 | O43570 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CA7 | P43166 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.35 |
| ▸ | STAT3 | P40763 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6052037 | 0.86 | CA12 (0.47) | MAPTCA12CA1CA2CA7 | |
| SCHEMBL9172789 | 0.85 | CA12 (0.46) | MAPTCA12CA1CA2CA7 | |
| Silver SCHEMBL9172794 | 0.84 | KDM4E (0.35) | MAPTGAACA12CA1CA2 | |
| SCHEMBL8953202 | 0.83 | KDM4E (0.41) | MAPTABCG2GAACA12CA1 | |
| SCHEMBL11022639 | 0.82 | ALPL (0.41) | MAPTABCG2GAACA12CA1 | |
| SCHEMBL3794387 | 0.79 | MAPT (0.37) | MAPTGAAMAPK1KDM4ENR4A2 | |
| SCHEMBL1080724 | 0.76 | QPCT (0.44) | MAPTALDH1A1KDM4EMEN1HPGD | |
| SCHEMBL5702607 | 0.76 | KDM4E (0.40) | MAPTALDH1A1MAPK1KDM4EHIF1A | |
| SCHEMBL1080091 | 0.75 | PARP1 (0.42) | MAPTABCG2GAAALDH1A1TSHR | |
| SCHEMBL9172863 | 0.74 | KDM4E (0.39) | MAPTALDH1A1MAPK1KDM4EHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3660003-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2024-01-24 | — | — | EP | disclosed |
| US-11713311-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-08-01 | — | — | US | disclosed |
| US-20220388995-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-12-08 | — | — | US | disclosed |
| US-11230541-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-01-25 | — | — | US | disclosed |
| US-20200231579-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-07-23 | — | — | US | disclosed |
| EP-3660003-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2020-06-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11230541-B2 | Heterocyclic compound | GRIN1, GRIN2A, GRIN2B | MAPT 213/4885ABCG2 2108/4885GAA 4568/4885 |
| US-20200231579-A1 | HETEROCYCLIC COMPOUND | GRIN1, GRIN2A, GRIN2B | MAPT 213/4885ABCG2 2108/4885GAA 4568/4885 |
| US-11713311-B2 | Heterocyclic compound | GRIN1, GRIN2A, GRIN2B | MAPT 213/4885ABCG2 2108/4885GAA 4568/4885 |
| US-20220388995-A1 | HETEROCYCLIC COMPOUND | GRIN1, GRIN2A, GRIN2B | MAPT 213/4885ABCG2 2108/4885GAA 4568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.